


Data Sheet

Product Information

Catalog Number	BP10252
Product Name	Larotrectinib
Description	Larotrectinib is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).
Targets&IC50	TRK: 2-20 nM
In vivo	Mice were maintained under aseptic conditions. The care and treatment of experimental animals was in accordance with institutional guidelines. 5×10^5 KM12 cells were injected subcutaneously into the dorsal flank area of the mice. Tumor volume was monitored by direct measurement with calipers and calculated by the formula: $\text{length} \times (\text{width}^2)/2$. Following the establishment of tumor and when the tumor size was between 150–200 mm ² , mice were randomly selected to receive diluent, 60 mg/kg/dose or 200 mg/kg/dose of Larotrectinib(LOXO-101). LOXO-101 was administered by oral gavage once daily for 14 days. After the last dose, tissue and blood were collected at 3, 6 and 24 hours post-treatment.
Synonyms	LOXO-101, ARRY-470
CAS No.	1223403-58-4
Chemical Formula	C ₂₁ H ₂₂ F ₂ N ₆ O ₂
Molecular Weight	428.444
Solubility	DMSO: 4.6 mg/mL (10.74 mM)
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year

Chemical Structure
OR
Tested Image



Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

<https://www.purduebio.com>

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022